Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/2/2026

1. META
2. AWK
3. LMN
4. CSGP
5. DOLE
6. LEVI
7. SPY
8. STZ
9. CVEO
10. ARES

Go back to Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn
(NASDAQ: XAIR) Delayed: 0.47 --0 (-0%)
Previous Close $0.47    52 Week High $ 
Open $0.47    52 Week Low $ 
Day High $0.47    P/E N/A 
Day Low $0.47    EPS $ 
Volume 456